Dyne Therapeutics (DYN) Insider Jason Rhodes Sells $6.6M of Stock
Jason Rhodes sold 309,268 shares of Dyne Therapeutics, Inc., valued at $6.58 million.
Reviewed by automated data checks against the source filing. How we make and check alerts
Jason Rhodes sold 309,268 shares of Dyne Therapeutics, Inc. ($DYN) at an average price of $21.28, worth about $6.58 million, on June 26, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $DYN is up 9.1% after 1 week, up 22.4% after 1 month and down 31.9% to date (from the $20.94 close on Jun 26, 2026).
DYN
Dyne Therapeutics, Inc.
Key Points
- Jason Rhodes sold 309,268 shares of Dyne Therapeutics, Inc. on June 26, 2026, for approximately $6.58 million.
- Dyne Therapeutics, Inc. has a market cap of around $3.46 billion and a 52-week range of $8.06 to $25.00.
- Analysts maintain a strong buy consensus with a target mean price of $38.25 for Dyne Therapeutics, Inc.
Get $DYN trade alerts by text
We text you when insiders, Congress or big funds trade $DYN. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Dyne Therapeutics, Inc. alert may contain errors. Disclosures
Jason Rhodes, a significant insider at Dyne Therapeutics, Inc. (NasdaqGS: DYN), sold 309,268 shares of the company on June 26, 2026. The transaction, which was planned, amounted to approximately $6.58 million, with each share priced at $21.28.
Insider Buying and Selling at Dyne Therapeutics, Inc.
Jason Rhodes has been actively selling shares of Dyne Therapeutics. In addition to the June 26 transaction, he sold 195,427 shares on June 29 at an average price of $21.14, and 24,100 shares on June 25 at $21.10. These sales were also planned. Another insider, Erick Lucera, the Chief Financial Officer, sold 2,362 shares on June 25 at $20.37, but this was not under a planned sale.
Dyne Therapeutics, Inc. Stock Up 29.8%
Shares of Dyne Therapeutics, Inc. traded near $21.26 on Wednesday. The company has a market cap of about $3.46 billion and is not currently profitable, resulting in no meaningful P/E ratio. Dyne's stock has seen a 52-week low of $8.06 and a high of $25.00. It maintains a 50-day moving average of $18.41 and a 200-day moving average of $17.85. The company's current ratio is strong at 19.92, with a quick ratio of 18.97 and a debt-to-equity ratio of 19.50.
Analysts Set New Price Targets
Analysts have maintained a strong buy consensus for Dyne Therapeutics, Inc., with a target mean price of $38.25. On May 15, 2026, Evercore ISI Group maintained a buy rating with a $33.00 price target. Bernstein, on May 13, 2026, maintained a hold rating with a target of $24.00. Other firms like Chardan Capital and Morgan Stanley have also maintained buy ratings with targets as high as $50.00.
About Dyne Therapeutics
Dyne Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts. It focuses on developing therapeutics for neuromuscular diseases, including myotonic dystrophy type 1 and Duchenne muscular dystrophy, using its FORCE platform. Led by CEO John G. Cox, the company employs 263 people and is working on treatments for rare muscle diseases.
Bottom Line
Jason Rhodes' recent sale of Dyne Therapeutics shares is part of a planned series of transactions. The company's stock performance remains strong, with a market cap of $3.46 billion and a promising analyst outlook. Investors will continue to watch for updates on its therapeutic developments and financial performance.
Related Filing Alerts
Source: Jason Rhodes's Form 4 filing on $DYN (Jun 26, 2026). Find the original filing: DYN Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts